Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Abb. 0: FÜR ÖSTERREICH: Weitere Informationen: Servier, Mariahilfer Straße 20/5, 1070 Wien, Tel. 01/524 39 99 Aktuelles Bild - Abb. 1: EUROPA-Studie Abb. 2: Studientrends - ACE-Hemmer Abb. 3: ACE-Hemmung - Benefit Abb. 4: KHK - Sekundärprävention Abb. 5: KHK - Sekundärprävention Abb. 6: Endotheliale Dysfunktion Zum letzten Bild
Abbildung 1: EUROPA-Studie
EUROPA (EUropean trial on Reduction Of cardiac events with Perindopril in stable Artery coronary disease) is the largest and longest study ever conducted in patients with stable coronary disease. It was announced at ESC in Vienna on the 31st of August 2003 during an official hotline session. EUROPA is considered as a reference study for the initiation of the ACEI perindopril 8 mg once daily as chronic treatment in all patients with stable coronary artery disease.
 
EUROPA-Studie
Vorheriges Bild Nächstes Bild   


Abbildung 1: EUROPA-Studie
EUROPA (EUropean trial on Reduction Of cardiac events with Perindopril in stable Artery coronary disease) is the largest and longest study ever conducted in patients with stable coronary disease. It was announced at ESC in Vienna on the 31st of August 2003 during an official hotline session. EUROPA is considered as a reference study for the initiation of the ACEI perindopril 8 mg once daily as chronic treatment in all patients with stable coronary artery disease.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung